TCGA-33-4566-01A-01R-1443-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 40
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- MYC_TARGETS_V1+0.590
- E2F_TARGETS+0.560
- INTERFERON_GAMMA_RESPONSE+0.540
- MYC_TARGETS_V2+0.540
- OXIDATIVE_PHOSPHORYLATION+0.480
- ALLOGRAFT_REJECTION+0.470
- G2M_CHECKPOINT+0.450
- TNFA_SIGNALING_VIA_NFKB+0.390
- IL6_JAK_STAT3_SIGNALING+0.370
Top 10 suppressed
- MYOGENESIS-0.250
- NOTCH_SIGNALING-0.230
- HEDGEHOG_SIGNALING-0.210
- KRAS_SIGNALING_DN-0.090
- UV_RESPONSE_DN-0.060
- BILE_ACID_METABOLISM-0.050
- WNT_BETA_CATENIN_SIGNALING-0.050
- CHOLESTEROL_HOMEOSTASIS-0.030
- MITOTIC_SPINDLE-0.010
- APICAL_JUNCTION+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.922 |
| 2 | TCGA-21-5787-01A-01R-1635-07 | — | cohortA4 | 0.914 |
| 3 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.912 |
| 4 | SRR6013500 | — | cohortA1 | 0.900 |
| 5 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.899 |
| 6 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.892 |
| 7 | TCGA-22-0940-01A-01R-0692-07 | — | cohortSQ1 | 0.892 |
| 8 | SRR6013499 | — | cohortA1 | 0.889 |
| 9 | MDT-AP-0368 | Med | Medulloblastoma | 0.889 |
| 10 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |